|
VGLL4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.07539998917395E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.45249999805586E-08 |
| Normal-vs-Stage2 |
3.429800E-04 |
| Normal-vs-Stage3 |
1.20050003271643E-09 |
| Normal-vs-Stage4 |
1.88139948065214E-10 |
| Stage1-vs-Stage2 |
5.701800E-02 |
| Stage1-vs-Stage3 |
1.440990E-01 |
| Stage1-vs-Stage4 |
3.117600E-02 |
| Stage2-vs-Stage3 |
8.379100E-03 |
| Stage2-vs-Stage4 |
1.539030E-03 |
| Stage3-vs-Stage4 |
3.438800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.29620000791186E-09 |
| Normal-vs-AfricanAmerican |
4.750400E-04 |
| Normal-vs-Asian |
4.2744000000039E-05 |
| Caucasian-vs-AfricanAmerican |
4.139000E-01 |
| Caucasian-vs-Asian |
3.066300E-02 |
| AfricanAmerican-vs-Asian |
5.055200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.19320000546708E-08 |
| Normal-vs-Female |
6.13460005016719E-09 |
| Male-vs-Female |
8.748800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.89659999716829E-08 |
| Normal-vs-Age(41-60Yrs) |
1.62009999860047E-08 |
| Normal-vs-Age(61-80Yrs) |
5.83890047423097E-10 |
| Normal-vs-Age(81-100Yrs) |
1.606330E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.034000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.120400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.201700E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.631360E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.955800E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.786800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.67650000000497E-05 |
| Classical-VS-Follicular |
3.274000E-01 |
| Classical-VS-Other |
8.171200E-01 |
| Classical-VS-Normal |
4.34739999555234E-08 |
| Tall-VS-Follicular |
8.10760000000688E-05 |
| Tall-VS-Other |
1.611760E-01 |
| Tall-VS-Normal |
5.50759438056048E-12 |
| Follicular-VS-Other |
9.023800E-01 |
| Follicular-VS-Normal |
2.04459999997297E-06 |
| Other-VS-Normal |
3.397800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.41609999784842E-08 |
| Normal-vs-N1 |
2.32419999912636E-08 |
| N0-vs-N1 |
3.685200E-01 |
|
|
